In a large international clinical trial (ODYSSEY OUTCOMES) involving 18,924 patients from 57 countries who had suffered a recent heart attack or threatened heart attack, researchers and scientists around the world, including Dr. Michael Szarek, chair and professor of the Department of Epidemiology & Biostatistics at the SUNY Downstate Medical Center School of Public Health, have found that the cholesterol-lowering drug alirocumab reduced the chance of having additional heart problems or stroke in these high-risk patients.
Read more about the ODYSSEY OUTCOMES study.
At the American College of Cardiology Conference (ACC) last week, Dr. Szarek moderated a poster presentation and co-authored three oral presentations, one of which discussed the ODYSSEY OUTCOMES study shared above.